Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Ibc Pharmaceuticals Inc patents


Recent patent applications related to Ibc Pharmaceuticals Inc. Ibc Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Ibc Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Ibc Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Ibc Pharmaceuticals Inc-related inventors


Bispecific antibodies that neutralize tnf-alpha and il-6: novel therapeutic agents for autoimmune disease

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one anti-tnf-α antibody or antigen-binding fragment thereof and at least one anti-il-6 antibody or antigen-binding fragment thereof. Preferably, the bispecific antibody is in the form of a dnl® complex. ... Ibc Pharmaceuticals Inc

Disease therapy by inducing immune response to trop-2 expressing cells

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for trop-2 (egp-1) and at least one binding site for cd3. The bispecific antibodies are of use for inducing an immune response against a trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. ... Ibc Pharmaceuticals Inc

Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors

The present invention concerns methods and compositions comprising an anti-igf-1r antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer. ... Ibc Pharmaceuticals Inc

Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one anti-tnf-α antibody or antigen-binding fragment thereof and at least one anti-il-6 antibody or antigen-binding fragment thereof. Preferably, the bispecific antibody is in the form of a dnl® complex. ... Ibc Pharmaceuticals Inc

Combination therapy for inducing immune response to disease

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for trop-2 (egp-1) and at least one binding site for cd3. The bispecific antibodies are of use for inducing an immune response against a trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. ... Ibc Pharmaceuticals Inc

Combination therapy with t-cell redirecting bispecific antibodies and checkpoint inhibitors

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for a tumor-associated antigen (taa) and at least one binding site for an antigen expressed on an effector t cell, nk cell, monocyte or neutrophil. The bispecific antibodies are of use for inducing an immune response against a taa-expressing tumor. ... Ibc Pharmaceuticals Inc

T-cell redirecting bispecific antibodies for treatment of disease

The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex. ... Ibc Pharmaceuticals Inc

Disease therapy by inducing immune response to trop-2 expressing cells

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for trop-2 (egp-1) and at least one binding site for cd3. The bispecific antibodies are of use for inducing an immune response against a trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. ... Ibc Pharmaceuticals Inc

Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology

The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-mab dnl complex comprises an igg antibody attached to two ad (anchor domain) moieties and four cytokines, each attached to a ddd (docking and dimerization domain) moiety. ... Ibc Pharmaceuticals Inc

Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses

The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. ... Ibc Pharmaceuticals Inc

Dock-and-lock (dnl) complexes for therapeutic and diagnostic use

Disclosed herein are methods and compositions dock and lock (dnl) complexes comprising an ad moiety selected from an akap protein and a ddd moiety selected from a protein kinase a regulatory subunit. Also disclosed are fusion proteins comprising an ad moiety or ddd moiety attached to an effector moiety. ... Ibc Pharmaceuticals Inc

Tetrameric cytokines with improved biological activity

The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-mab dnl complex comprises an igg antibody attached to two ad (anchor domain) moieties and four cytokines, each attached to a ddd (docking and dimerization domain) moiety. ... Ibc Pharmaceuticals Inc

T-cell redirecting bispecific antibodies for treatment of disease

The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex. ... Ibc Pharmaceuticals Inc

Combination therapy for inducing immune response to disease

The present invention concerns combinations of two or more agents for inducing an immune response to cancer or infectious disease. Agents may include leukocyte redirecting complexes, antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. ... Ibc Pharmaceuticals Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Ibc Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Ibc Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###